1. Home
  2. GNTX vs GRFS Comparison

GNTX vs GRFS Comparison

Compare GNTX & GRFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Gentex Corporation

GNTX

Gentex Corporation

HOLD

Current Price

$24.12

Market Cap

5.2B

ML Signal

HOLD

Logo Grifols S.A.

GRFS

Grifols S.A.

HOLD

Current Price

$9.28

Market Cap

6.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GNTX
GRFS
Founded
1974
1940
Country
United States
Spain
Employees
N/A
N/A
Industry
Auto Parts:O.E.M.
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.2B
6.2B
IPO Year
N/A
2006

Fundamental Metrics

Financial Performance
Metric
GNTX
GRFS
Price
$24.12
$9.28
Analyst Decision
Buy
Hold
Analyst Count
6
2
Target Price
$28.33
$10.15
AVG Volume (30 Days)
2.9M
469.7K
Earning Date
01-30-2026
07-28-2022
Dividend Yield
1.96%
1.55%
EPS Growth
N/A
N/A
EPS
1.74
0.64
Revenue
$2,534,268,965.00
$8,821,017,248.00
Revenue This Year
$7.37
$5.36
Revenue Next Year
$5.07
$5.15
P/E Ratio
$14.07
$17.79
Revenue Growth
9.55
7.31
52 Week Low
$20.28
$6.19
52 Week High
$29.38
$11.14

Technical Indicators

Market Signals
Indicator
GNTX
GRFS
Relative Strength Index (RSI) 55.23 48.88
Support Level $22.31 $9.23
Resistance Level $25.14 $9.60
Average True Range (ATR) 0.63 0.19
MACD 0.08 0.00
Stochastic Oscillator 73.14 53.61

Price Performance

Historical Comparison
GNTX
GRFS

About GNTX Gentex Corporation

Gentex was founded in 1974 to produce smoke-detection equipment. The company sold its first glare-control interior mirror in 1982 and its first model using electrochromic technology in 1987. Automotive revenue is about 98% of total revenue. The company is constantly developing new applications for the technology to remain on top. Sales in 2024 totaled about $2.3 billion with 47.7 million mirrors shipped. The unit mix breaks out as 63% interior and 37% exterior, versus 31% exterior in 2019. The company is based in Zeeland, Michigan.

About GRFS Grifols S.A.

Grifols SA one of is global specialty plasma therapeutics companies developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value. These protein-based therapies extend and enhance the lives of individuals who suffer from chronic and acute, often life-threatening, conditions, including primary and secondary immunological deficiencies, Chronic Inflammatory Demyelinating Polyneuropathy, immune-mediated ITP. Products and services are used to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases and a range of other medical conditions. Majority of revenue is from USA.

Share on Social Networks: